PDF
Word
This version of the form is not currently in use and is provided for reference only. Download this version of
Form HLTH5468
for the current year.
Form HLTH5468 Special Authority Request - Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis - British Columbia, Canada
Form HLTH5468 Special Authority Request - Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis is used in British Columbia, Canada to request special authorization for the use of the medications Nintedanib and Pirfenidone in the treatment of Idiopathic Pulmonary Fibrosis.
The Form HLTH5468 Special Authority Request - Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis in British Columbia, Canada is typically filed by a prescribing healthcare provider or a specialist.
FAQ
Q: What is the purpose of the Form HLTH5468?
A: The purpose of Form HLTH5468 is to request special authority for the medication Nintedanib and Pirfenidone for the treatment of Idiopathic Pulmonary Fibrosis in British Columbia, Canada.
Q: What medications are being requested in this form?
A: The medications being requested in this form are Nintedanib and Pirfenidone.
Q: What is Idiopathic Pulmonary Fibrosis?
A: Idiopathic Pulmonary Fibrosis is a progressive lung disease that causes scarring of the lungs.
Q: Who can use this form?
A: Healthcare providers can use this form to request special authority for their patients with Idiopathic Pulmonary Fibrosis in British Columbia, Canada.
Q: What is special authority?
A: Special authority is a process by which certain medications are approved for coverage by the government based on specific criteria.
Q: What is the purpose of Nintedanib and Pirfenidone in the treatment of Idiopathic Pulmonary Fibrosis?
A: Nintedanib and Pirfenidone are medications that can help slow down the progression of Idiopathic Pulmonary Fibrosis and improve lung function.
Download Form HLTH5468 Special Authority Request - Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis - British Columbia, Canada
1
2
